PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $4.17 per share for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2024-11-07
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2019-03-31 was $25.64, a 21.49% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2018-03-31 was $32.66, a 17.94% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2017-03-31 was $39.80, a 46.58% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2016-03-31 was $74.51, a 15.49% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2021 was $7.96.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2019 was $26.27, a 16.42% decline from fiscal 2018.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2018 was $31.43, a 4.04% increase from fiscal 2017.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2017 was $30.21, a 58.74% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2024-09-30 | $4.17 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $4.17 10-Q · filed 2024-08-01 | |||
| 2021-12-31 | $7.96 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $8.32 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $12.66 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $26.27 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $25.06 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $25.41 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $25.64 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $31.43 10-K · filed 2020-02-28 | |||
| 2018-09-30 | $32.46 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $32.95 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $32.66 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $30.21 10-K · filed 2019-03-01 | |||
| 2017-09-30 | $30.28 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $30.42 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $39.80 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $73.22 10-K · filed 2018-03-09 | |||
| 2016-09-30 | $74.02 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $74.49 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $74.51 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $102.31 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $110.20 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $115.44 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $88.17 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $46.48 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |